Zejula

Zejula, also known as niraparib tosylate monohydrate, is an oral targeted therapy designed for the management of certain ovarian, fallopian tube, and primary peritoneal cancers. It belongs to the class of poly (ADP-ribose) polymerase (PARP) inhibitors, which interfere with DNA repair mechanisms in cancer cells. By inhibiting PARP enzymes, Zejula prevents cancer cells from repairing damaged DNA, leading to cell death, particularly in cells that already have deficiencies in DNA repair pathways, such as those with BRCA mutations.
The medicine is taken orally and is absorbed efficiently, allowing for consistent inhibition of PARP activity over time. Zejula is often used in patients whose disease has responded to platinum-based therapies, where it helps maintain disease control and delay progression. Clinical studies have shown that the therapy can significantly reduce the risk of disease progression and improve progression-free survival, providing meaningful benefits for long-term disease management.
Common effects may include fatigue, nausea, vomiting, decreased appetite, abdominal pain, and hematologic changes such as low blood counts. Less frequently, patients may experience hypertension, insomnia, or liver enzyme elevations. Regular monitoring of blood counts and liver function is recommended to ensure safety and optimize therapy.
Zejula is metabolized primarily by the liver and eliminated through standard metabolic pathways, allowing for predictable pharmacokinetics. Overall, Zejula represents a major advancement in precision oncology by targeting the specific vulnerabilities of cancer cells. Its mechanism of action provides an effective non-chemotherapy-based approach to controlling disease, improving quality of life, and extending the period of disease stability in patients worldwide.